Innovent Biologics, Inc.

Headquarters: Suzhou, China

Employees: 5,568

CEO: Dr. De-Chao Yu Ph.D.

HKEX: 1801 -1.13%

Market Cap

HK$63.29 Billion

HKD as of Jan. 1, 2024

US$8.10 Billion

history Market Cap History

Innovent Biologics, Inc. market capitalization over time

Evolution of Innovent Biologics, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Innovent Biologics, Inc.

Detailed Description

Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-303, an adalimumab biosimilar for autoimmune diseases; and IBI-305, a bevacizumab biosimilar to treat metastatic colorectal cancer and non-small cell lung cancer. In addition, it develops IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-308, a human monoclonal antibody for lung, esophageal, and gastric cancer, as well as Hodgkin's lymphoma; and IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further, the company develops IBI-101, an anti-OX40 agonistic antibody for advanced solid tumors; and IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with The University of Texas MD Anderson Cancer Center to co-develop TYVYT, a sintilimab injection; Roche Group for the discovery and development of bispecific antibodies and multiple cell therapies; Ascentage Pharma for joint commercialization of Olverembatinib; NeoCura Bio-Medical Technology Co. Ltd. to study the combination therapy of Sintilimab and neoantigen vaccine NEO_PLIN2101 for cancer treatment; and Eli Lilly and Company, and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, China.


"Bulls make money...
Bears make money...
Pigs get slaughtered!"

Stop guessing, unlock Financial AI.

(Don't be a pig.)

Stocks & Indices

Innovent Biologics, Inc. has the following listings and related stock indices.

Stock: HKEX: 1801 wb_incandescent

Stock: FSX: 6IB wb_incandescent

Stock: OTC: IVBXF wb_incandescent



168 Dongping Street

Suzhou Industrial Park

Suzhou, 215123


Phone: 86 512 6956 6088

Fax: 86 512 6956 6088